. 2010 Sep 6;32(1):145–157. doi: 10.1007/s13277-010-0108-7

Table 1.

Patients characteristics

Patients	Age	TNM	HT	LN(+)/LN	ER	PR	ErbB2
1^a	43	T2N0M0	ILC	0/13	+	+	−
2^a	44	T2N0M0	ILC	0/29	+	+	−
3^a	74	T1N0M0	IDC	0/28	+	+	−
4	42	T3N0M0	IDC	0/22	+	+	−
5	60	T2N0M0	ILC	0/27	−	+	−
6	41	T1N0M0	IDC	0/10	+	+	−
7	47	T2N1M0	IDC	3/19	+	+	+
8^a	49	T1N2M0	IDC	6/25	+	+	+
9^a	59	T2N3M0	ILC	13/27	−	+	−
10^a	41	T2N3M0	IDC	10/19	−	+	−
11	70	T2N2M0	IDC	5/15	−	−	−
12	65	T1N1M0	IDC	2/18	−	−	−
13	81	T2N3M0	IDC	12/16	+	−	+
14	40	T2N1M0	IDC	2/19	−	+	−

TNM (AJCC, 2002)

HT histologycal type, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, ER estrogen receptor, PR progesterone receptor, LN(+)/LN number of involved lymph nodes/dissected, LN (+) positive immuno-expression, (−) negative immuno-expression

^aSamples used in cDNA microarray experiments